BIO 2013 Wednesday Roundup: Roche Partnering, Crowdfunding, Alzheimer’s and Deal Trend Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Our survey of news and notes from the third day of the BIO 2013 conference includes insights from panel discussions about the environments for licensing deals and Alzheimer’s disease research, an interview with a Roche exec about the company’s partnering strategy, and news about a crowdfunding portal that will connect VCs and companies with accredited individual investors.
You may also be interested in...
Deals Of The Week Watches Crowdfunders Multiply Like Rabbits
VentureHealth combines the best in venture and crowdfunding, and has two exits to show for it. Plus Valeant buys Bausch & Lomb, GSK buys Okairos, AZ buys Omthera, while ThromboGenics/Array, Pfizer/UCSF, and Amgen/Astellas do deals.
BIO 2013: Biosimilars, Drug Pricing, Business Development And Innovation
Pharma and biotech leaders discussed the biosimilars landscape, paying for innovation beyond rare disease drugs, emerging markets and partnering trends at BIO 2013 in Chicago.
Guidance For Drugs To Target Early Alzheimer’s Notes Lack Of Metrics, Biomarkers
FDA’s new draft guidance on developing drugs to treat people in the early stages of Alzheimer’s disease, before any noticeable dementia sets in, is sure to generate further discussion and comment on how best to identify and measure the disease and its progression.